Yes, proteomic markers can predict treatment response. For instance, the presence of the KRAS mutation in colorectal cancer patients can predict resistance to certain EGFR inhibitors. By identifying these markers, clinicians can choose more effective therapies and avoid treatments that are unlikely to work.
